Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid

The EPO published Intellia Therapeutics' patent application EP3946285A1 as a granted patent, establishing intellectual property protection for CRISPR-based TTR gene editing compositions co-administered with corticosteroids for treating hereditary ATTR amyloidosis. The patent claims priority to 2020 filings and covers therapeutic uses of nucleic acid editing enzymes (C12N 9/22) in combination with therapeutic nucleotides (A61K 31/713).

Affected parties include biotech and pharmaceutical companies developing gene therapies for transthyretin amyloidosis, including competitors like Alnylam and Regeneron. Manufacturers of CRISPR-based therapeutics for neurological diseases should assess freedom-to-operate implications. Healthcare providers conducting clinical trials in gene editing for ATTR amyloidosis should verify institutional licensing arrangements.